Abstract
Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.
Collapse